Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease
Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer
Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC
Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC
† Study has passed its completion date and status has not been verified in more than two years.